Synmosa Biopharma Corporation

TPEX:4114 Stock Report

Market Cap: NT$15.4b

Synmosa Biopharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Zhihui Lin

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure21yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure7yrs

Recent management updates

Recent updates

Analysis Article • Apr 04

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Could Synmosa Biopharma Corporation ( GTSM:4114 ) be an attractive dividend share to own for the long haul? Investors...
Analysis Article • Mar 08

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Investors can buy low cost index fund if they want to receive the average market return. But in any diversified...
Analysis Article • Jan 31

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Synmosa Biopharma (GTSM:4114) has had a rough week with its share price down 8.3%. But if you pay close attention, you...
Analysis Article • Jan 05

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Dec 09

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...

CEO Compensation Analysis

How has Zhihui Lin's remuneration changed compared to Synmosa Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

NT$807m

Dec 31 2025n/an/a

NT$822m

Sep 30 2025n/an/a

NT$770m

Jun 30 2025n/an/a

NT$726m

Mar 31 2025n/an/a

NT$710m

Dec 31 2024n/an/a

NT$685m

Sep 30 2024n/an/a

NT$718m

Jun 30 2024n/an/a

NT$689m

Mar 31 2024n/an/a

NT$650m

Dec 31 2023n/an/a

NT$595m

Sep 30 2023n/an/a

NT$585m

Jun 30 2023n/an/a

NT$562m

Mar 31 2023n/an/a

NT$800m

Dec 31 2022n/an/a

NT$799m

Sep 30 2022n/an/a

NT$735m

Jun 30 2022n/an/a

NT$693m

Mar 31 2022n/an/a

NT$368m

Dec 31 2021n/an/a

NT$304m

Sep 30 2021n/an/a

NT$288m

Jun 30 2021n/an/a

NT$293m

Mar 31 2021n/an/a

NT$634m

Dec 31 2020NT$5mNT$4m

NT$638m

Compensation vs Market: Insufficient data to establish whether Zhihui's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Insufficient data to compare Zhihui's compensation with company performance.

CEO

Zhihui Lin (42 yo)

21yrs
Tenure
NT$4,710,000
Compensation

Mr. Zhihui Lin serves as Chairman at Synmosa Biopharma Corporation and serves as its Director since May 16, 2019. He is Currently holding concurrent positions in this company and other companies which incl...

Board Members

NamePositionTenureCompensationOwnership
Zhihui Lin
Chairman21yrsNT$4.71mno data
Lai-Shou Su
Independent Directorno datano datano data
San-Chien Tu
Additional Independent Director2.8yrsno datano data
Xiang-Lang Liu
Independent Director23.3yrsNT$1.07mno data
Xiu-Mei Lin
Independent Director7yrsNT$1.19m0.00098%
NT$ 151.0k
You-Peng Zhang
Representative Director7yrsNT$1.09m0.98%
NT$ 151.4m
Li-Wen Huang
Representative Director17.3yrsNT$1.09m0.55%
NT$ 85.0m
Huilan Qiu
Independent Director2.3yrsno data1.77%
NT$ 273.0m
Tzen-Wen Chen
Independent Directorno datano datano data
Chi-Wen Chen
Independent Directorno datano datano data
7.0yrs
Average Tenure
43yo
Average Age

Experienced Board: 4114's board of directors are considered experienced (7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/21 08:20
End of Day Share Price 2026/05/21 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Synmosa Biopharma Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xiaowei HuangMasterlink Securities Investment Advisory
Yijun ChenSinoPac Securities Investment Service